OpenURL Connection Search

Select item for more details and to access through your institution.

A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND DACARBAZINE (APVD) FOR PATIENTS WITH UNTREATED CLASSICAL HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 572, doi. 10.1002/hon.21_2632
By:
- Lynch, R.C.;
- Smith, S.D.;
- Shadman, M.;
- Ujjani, C.S.;
- Kurtz, D.M.;
- Coye, H.;
- Till, B.G.;
- Warren, E.H.;
- Shustov, A.R.;
- Maloney, D.G.;
- Tseng, Y.D.;
- Gopal, A.K.
Publication type:
Article
TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 178, doi. 10.1002/hon.135_2629
By:
- Falchi, L.;
- Lue, J.K.;
- Montanari, F.;
- Marchi, E.;
- Amengual, J.E.;
- Sawas, A.;
- Deng, C.;
- Khan, K.;
- Kim, H.A.;
- Rada, A.;
- Malanga, M.;
- Francescone, M.F.;
- Soderquist, C.R.;
- Park, D.C.;
- Bhagat, G.;
- Sokol, L.;
- Shustov, A.R.;
- O'Connor, O.A.
Publication type:
Article
A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND DACARBAZINE (APVD) FOR PATIENTS WITH UNTREATED CLASSICAL HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 572, doi. 10.1002/hon.21_2632
By:
- Lynch, R.C.;
- Smith, S.D.;
- Shadman, M.;
- Ujjani, C.S.;
- Kurtz, D.M.;
- Coye, H.;
- Till, B.G.;
- Warren, E.H.;
- Shustov, A.R.;
- Maloney, D.G.;
- Tseng, Y.D.;
- Gopal, A.K.
Publication type:
Article
TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 178, doi. 10.1002/hon.135_2629
By:
- Falchi, L.;
- Lue, J.K.;
- Montanari, F.;
- Marchi, E.;
- Amengual, J.E.;
- Sawas, A.;
- Deng, C.;
- Khan, K.;
- Kim, H.A.;
- Rada, A.;
- Malanga, M.;
- Francescone, M.F.;
- Soderquist, C.R.;
- Park, D.C.;
- Bhagat, G.;
- Sokol, L.;
- Shustov, A.R.;
- O'Connor, O.A.
Publication type:
Article
IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT.
Published in:
Hematological Oncology, 2017, v. 35, p. 78, doi. 10.1002/hon.2437_66
By:
- Fox, C.P.;
- Bellei, M.;
- Manni, M.;
- Kim, S.J.;
- Ko, Y.H.;
- Shustov, A.R.;
- Cabrera, M.E.;
- Chiattone, C.S.;
- Horwitz, S.M.;
- Spina, M.;
- Advani, R.H.;
- Angrilli, F.;
- De Souza, C.A.;
- Dlouhy, I.;
- Fernandez ‐ Alvarez, R.;
- Gabús, R.;
- Hitz, F.;
- Laszlo, D.;
- Montoto, S.;
- Nagler, A.
Publication type:
Article

Found: 5

A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND DACARBAZINE (APVD) FOR PATIENTS WITH UNTREATED CLASSICAL HODGKIN LYMPHOMA.

TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY.

A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND DACARBAZINE (APVD) FOR PATIENTS WITH UNTREATED CLASSICAL HODGKIN LYMPHOMA.

TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY.

IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT.